ClinicalTrials.Veeva

Menu

Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia (STAMINA)

H

Hospital do Coracao

Status

Terminated

Conditions

Community-acquired Pneumonia
Acute Respiratory Distress Syndrome

Treatments

Procedure: Positive end-expiratory pressure titration with driving pressure control
Procedure: ARDSNet ventilatory strategy

Study type

Interventional

Funder types

Other
NETWORK

Identifiers

NCT04972318
stamina_trial

Details and patient eligibility

About

Randomized Controlled Trial Comparing Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia. The control strategy will be based on ARDSNet approach. The intervention group will receive a different ventilatory strategy based on positive end-expiratory pressure tailored according to compliance and limited driving pressure.

Full description

There is no consensus on the optimal ventilatory management of patients with community-acquired pneumonia that require mechanical ventilation and have acute respiratory distress syndrome. The traditional ventilatory approach (ARDSNet) is based on a fixed table for both end respiratory positive end-expiratory pressure according to inspired oxygen fraction. Alternatively, a strategy that tailors positive end-expiratory pressure according to compliance and limits driving pressure may be beneficial, but evidence is lacking.

We will perform an open label randomized controlled trial comparing both strategies.

Enrollment

214 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with community acquired pneumonia requiring invasive mechanical ventilation
  • Bilateral pulmonary infiltrates on chest imaging not fully explained by fluid overload in the opinion of the attending physician
  • One of the criteria below:
  • Oxygen inspired fraction above 50% with a positive end-expiratory pressure of at least 8 cmH2O to main peripheral oxygen saturation above 93%, OR
  • Arterial partial pressure of oxygen divided by inspired fraction of oxygen lower than 200 with PEEP values of at least 5 cmH2O

Exclusion criteria

  • Patients with inclusion criteria for more than 36 hours
  • Refusal of the patient´s legal representative
  • Acute neurologic disease (stroke, brain trauma, or any disease that may cause intracranial hypertension)
  • Patients with current airway fistula or barotrauma
  • Patients on chronic home use of oxygen due to underlying lung disease
  • Patients younger than 18 years
  • Patients not on full code status

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

214 participants in 2 patient groups

ARDSNet strategy
Active Comparator group
Description:
Patients will receive a mechanical ventilation strategy based on fixed values of positive end-expiratory pressure according to inspired fraction of oxygen. Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before. This arm is similar to the ARMA (Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome) trial.
Treatment:
Procedure: ARDSNet ventilatory strategy
STAMINA strategy
Experimental group
Description:
Patients will receive a mechanical ventilation strategy based on positive end-expiratory pressure tailored to achieve the optimal respiratory system compliance and to have driving pressure limited to 14 cmH2O. Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before.
Treatment:
Procedure: Positive end-expiratory pressure titration with driving pressure control

Trial contacts and locations

6

Loading...

Central trial contact

Israel S Maia, MSc; Rodrigo M Gurgel, BM

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems